<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697564</url>
  </required_header>
  <id_info>
    <org_study_id>181395</org_study_id>
    <nct_id>NCT03697564</nct_id>
  </id_info>
  <brief_title>Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).</brief_title>
  <official_title>Open Label Randomized Phase II Trial of Nivolumab + Cabiralizumab (BMS-986227, FPA008) + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hitendra Patel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stand Up To Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lustgarten Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if the combination of nivolumab + cabiralizumab +&#xD;
      gemcitabine can give prolonged disease control in patients with advanced pancreatic cancer&#xD;
      compared to gemcitabine alone.&#xD;
&#xD;
      Cabiralizumab is an antibody (a type of protein) that binds to a molecule called CSF-1r.&#xD;
      CSF-1r is a molecule present on different types of cells in your immune system that controls&#xD;
      parts of your immune system. Blocking CSF-lr could potentially stop the cancer cells which it&#xD;
      appears on from escaping the immune system, which could then act to kill the cancer cells.&#xD;
&#xD;
      Nivolumab is an anti-PD-1 antibody that boost the body's immune system. It works by attaching&#xD;
      to and blocking a molecule on white blood cells called PD-1. PD-1 is a protein that is&#xD;
      present on different types of cells in your immune system and controls parts of your immune&#xD;
      system by shutting it down. Antibodies that block PD-1 can potentially prevent PD-1 from&#xD;
      shutting down the immune system, thus allowing immune cells to recognize and destroy cancer&#xD;
      cells.&#xD;
&#xD;
      Gemcitabine is currently used to treat advanced or metastasized (spread) pancreatic cancer.&#xD;
      It is used in patients whose disease cannot be removed by surgery and who have already been&#xD;
      treated with other chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Working on getting accurate information for patients interested in the study.&#xD;
  </why_stopped>
  <start_date type="Actual">October 31, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>To estimate Progression Free Survival (PFS rates) at 6 months by RECIST1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Grade 2-5 Adverse Events assessed using NCI CTCAE v5.0 toxicity criteria</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pancreatic Cancer Stage IV</condition>
  <arm_group>
    <arm_group_label>gemcitabine +nivolumab + cabiralizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m2 IV on days 1, 8, and 15 Q4W</description>
    <arm_group_label>gemcitabine +nivolumab + cabiralizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]</intervention_name>
    <description>480mg IV on Day 1 Q4W</description>
    <arm_group_label>gemcitabine +nivolumab + cabiralizumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabiralizumab</intervention_name>
    <description>4mg/kg IV on day 1 and 15 Q4W</description>
    <arm_group_label>gemcitabine +nivolumab + cabiralizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed pancreatic adenocarcinoma with metastasis&#xD;
&#xD;
          -  Must be off their prior cytotoxic regimen a minimum of two weeks but no more than four&#xD;
             weeks from initiating trial treatment.&#xD;
&#xD;
        Measurable disease by RECIST 1.1.&#xD;
&#xD;
        Demonstrate adequate organ function&#xD;
&#xD;
        Normal Vitamin D level.&#xD;
&#xD;
        Able to submit an archival tumor specimen (primary or metastatic site). Patients with&#xD;
        cytology only that do not have adequate archived tumor specimen available, will require a&#xD;
        baseline biopsy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is currently participating and receiving trial therapy or has participated in a trial&#xD;
             of an investigational agent and received trial therapy or used an investigational&#xD;
             device within 3 weeks of the first dose of trial treatment.&#xD;
&#xD;
          -  Hypersensitivity to cabiralizumab, nivolumab, or gemcitabine or any of its excipients.&#xD;
&#xD;
          -  Previous malignancies (except non-melanoma skin cancers, and in situ bladder, gastric,&#xD;
             colorectal, endometrial, cervical/dysplasia, melanoma, or breast cancers) unless&#xD;
             complete remission was achieved at least 2 years prior to study entry and no&#xD;
             additional therapy is required during the study period.&#xD;
&#xD;
          -  Evidence of central nervous system (CNS) metastasis&#xD;
&#xD;
          -  Participants with active, known, or suspected autoimmune disease.&#xD;
&#xD;
          -  Current or history of clinically significant muscle disorders (e.g., myositis), recent&#xD;
             unresolved muscle injury, or any condition known to elevate serum CK levels.&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  Prior organ allograft or allogeneic bone marrow transplantation.&#xD;
&#xD;
          -  Any uncontrolled inflammatory GI disease including Crohn's Disease and ulcerative&#xD;
             colitis.&#xD;
&#xD;
          -  Evidence of coagulopathy or bleeding diathesis.&#xD;
&#xD;
          -  Has received prior therapy with a CSF-1R pathway inhibitors, anti-PD-1, anti-PD-L1,&#xD;
             anti PD-L2, anti-CTLA-4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hitendra Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Lowy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Hitendra Patel</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pancreating Cancer</keyword>
  <keyword>Cancer</keyword>
  <keyword>Stage IV</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>nivolumab</keyword>
  <keyword>cabiralizumab</keyword>
  <keyword>BMS-986227</keyword>
  <keyword>FPA008</keyword>
  <keyword>GemCaN</keyword>
  <keyword>Stand Up to Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

